Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Upcoming SlideShare
What to Upload to SlideShare
Next
Download to read offline and view in fullscreen.

0

Share

Download to read offline

Hepatobiliary brachytherapy

Download to read offline

Hepatobiliary brachytherapy is a niche area of research and this has been addressed in this slide set with opinion from discussants

Related Books

Free with a 30 day trial from Scribd

See all

Related Audiobooks

Free with a 30 day trial from Scribd

See all
  • Be the first to like this

Hepatobiliary brachytherapy

  1. 1. Dr Ajeet Kumar Gandhi MD (AIIMS); DNB; UICCF (MSKCC, USA) Assistant professor, Radiation oncology Dr RMLIMS, Lucknow Panel discussion: Common issues faced in hepato-biliary brachytherapy
  2. 2. Hepato-biliary brachytherapy  Hepatobiliary tumours consist of a constellation of tumours with surgical resection as primary modality of treatment  Radiotherapy has emerged in past few decades as an adjunct/bridge to surgical treatment  While the use of EBRT has been on rise, the use of brachytherapy is still limited to few centres across the world: Physician/Institute centric
  3. 3. Common issues faced in H-B brachytherapy  Awareness of BT as a modality for H-B tumors  Patient selection: EBRT vs. BT  Procedural complexities and presumed toxicities  Skills/Invasiveness of procedure  Sensitive organ/ limited tolerance  Paucity of literature regarding technique/results
  4. 4. H-B Brachytherapy Indications  Radical As a bridge to liver transplantation In small inoperable tumors or in combination with EBRT for un-resectable patients Hepato-cellular carcinoma Cholangiocarcinoma  Adjunctive (after non-radical excision, possibly combined with EBRT)
  5. 5. Tumour necrosis rates: 60-70% vs. 20- 30%
  6. 6. HDR-IBT in difficult case scenarios  Large tumors >7-12 cm  Hilar tumours  Unresectable HCC  Centrally located tumors  HCC with portal vein thrombus
  7. 7. Gandhi AK, Chauhan A, Rastogi M et al. RMLIMS
  8. 8. Gandhi AK, Chauhan A, Rastogi M et al. RMLIMS
  9. 9. Neo-adjuvant treatment protocols for hilar cholangiocarcinoma
  10. 10. EBRT combined with BT for biliary tumors
  11. 11. H-B Brachytherapy Indications  Palliative  Metastatic lesions: Colo-rectal, breast, pancreatic, neuro-endocrine, pancreatic, GI, RCC  Malignant biliary obstruction Primary cholangiocarcinoma Tumoral obstruction: GB, Pancreas, nodes at porta
  12. 12. Contemporary series on CT HDR- IBT for liver lesions
  13. 13. Treatment Techniques: Trans-hepatic 1) Cholangiogram : Site and length of the malignant stricture 2) Biliary drainage with minimum 10 French diameter catheter 3) BT blind-ended catheter (usually 5 or 6 French) through the biliary drainage 10 French catheter 4) Marker wire is then passed into the brachytherapy catheter 5) Treatment planning procedure
  14. 14. Treatment Techniques: Trans-duodenal endoscopic technique  ERCP: Site, length of involvement, extent of disease  Sphincterotomy: Cannulation of bile duct  Guide wire passed through and beyond stricture  Naso-biliary tube threaded over guide wire beyond stricture  Images acquired with radio-opaque markers  Planning and delivery
  15. 15. Imaging for planning  NCCT scan  CECT scan  CEMRI  PET-CT
  16. 16. Target volume and planning  2-D planning:  Clinical target length (1 cm proximal/distal)  Dose prescribed at 1 cm from source axis  3-D planning:  Image acquisition: CECT, MRI, PET-CT  Target delineation: GTV, CTV,PTV  OARs: Remaining liver, stomach, duodenum, spinal cord, small bowel
  17. 17. Dose prescription  Liver brachytherapy Radical: 15-20 Gray Palliative: 10-25 Gray  Biliary brachytherapy Radical: EBRT (30-40 Gray) with Brachytherapy (15-20 Gray) Palliative: 15-20 Gray
  18. 18. Dosimetric advantage of Interstitial Brachytherapy D4cm tumor shell>20Gy D3.6cm tumor shell>25Gy D3.2cm tumor shell >30Gy
  19. 19. Dose constraints for the OARs  Liver:  V5< 30-60% [Ricke 2016]  V10<30% [Colletini 2014]  Stomach  D1ml<12 Gray [Colletini 2014]  D1ml<15.5 Gy [Ricke 2006]  Hilar Structures  D1ml<12 Gray [Colletini 2014]  Duodenum, Small Bowel, Lung, Kidneys
  20. 20. Response Evaluation  Criteria: RECIST/PERCIST  Time of evaluation  Imaging modality: CECT MRI PET-CT
  21. 21. Take home message  Hepato-biliary brachytherapy is a safe, effective and applicable technique  The indications have expanded over the period of time  Volume delineation, dose constraints need to be better defined  In difficult to treat situations, HDR-IBT could be useful competitive modality  Prospective and multi-institutional studies are warranted  Teaching workshops would propagate knowledge and promote its use
  22. 22. Thank you!!

Hepatobiliary brachytherapy is a niche area of research and this has been addressed in this slide set with opinion from discussants

Views

Total views

19

On Slideshare

0

From embeds

0

Number of embeds

0

Actions

Downloads

1

Shares

0

Comments

0

Likes

0

×